The number of people who survive stage 4 cancer varies dramatically depending on the type of cancer, but more people are surviving it than ever before. Five-year survival rates for some stage 4 cancers have doubled or tripled in the past decade, while others remain stubbornly low. Across all types, the honest answer is that most stage 4 cancers are not curable in the traditional sense, but a growing minority of patients live years or even decades after diagnosis.
Survival Rates by Cancer Type
Stage 4 means cancer has spread from its original site to distant organs. Survival statistics are tracked as “5-year relative survival,” which measures the percentage of patients still alive five years after diagnosis compared to the general population. Here’s where the major cancers stand, based on the most recent federal data from the SEER program (covering 2013 to 2019 diagnoses):
- Prostate cancer: 40.1% five-year survival when metastatic
- Breast cancer: 31% five-year survival when metastatic
- Lung cancer: 10.5% five-year survival when metastatic
These numbers represent averages across all patients, including those diagnosed years ago with older treatments. For cancers diagnosed today, outcomes are likely somewhat better because newer therapies are now standard. Lung cancer is worth noting in particular: 51% of all lung cancer cases are already metastatic at the time of diagnosis, making that 10.5% figure relevant to a huge number of people.
Where Immunotherapy Changed the Math
The most dramatic improvement has been in metastatic melanoma. Before 2011, patients with stage 4 melanoma had a median survival of roughly 6 to 10 months with chemotherapy. That picture has transformed. In the landmark CheckMate 067 trial, patients who received a combination of two immunotherapy drugs had a 6.5-year overall survival rate of 49%. Nearly half were still alive more than six years later. Even with a single immunotherapy agent, 42% survived to that point.
Earlier data from phase II trials showed that 4-year survival rates for previously untreated melanoma patients on immunotherapy ranged from about 38% to 50%, depending on the dose. For patients who had already tried other treatments, 4-year survival was lower, in the range of 14% to 28%. The key finding across all of these studies is that patients who respond well to immunotherapy tend to stay in response for years, a pattern researchers call “durable survival.” This is fundamentally different from chemotherapy, where responses often fade within months.
Immunotherapy has also improved outcomes in metastatic lung cancer, bladder cancer, kidney cancer, and several other types, though the gains have been less dramatic than in melanoma. The general pattern is that a subset of patients responds exceptionally well, while the majority still faces a difficult prognosis.
What “Beating” Stage 4 Cancer Actually Means
Doctors are careful with the word “cure” when it comes to stage 4 cancer. The National Cancer Institute defines a cure as having no traces of cancer after treatment, with the cancer never coming back. In practice, doctors rarely use that word for metastatic disease. Instead, they talk about complete remission, meaning all detectable signs of cancer have disappeared, or “no evidence of disease” (NED), which means scans and tests can’t find any remaining cancer.
Some patients stay in complete remission for five years or more, which is the traditional threshold where certain cancers might be considered cured. But cancer cells can remain dormant in the body for years and reappear later. For this reason, many oncologists will say something like “there are no signs of cancer at this time” rather than declaring a patient cured. This isn’t pessimism. It reflects genuine biological uncertainty. Most cancers that return do so within the first five years, but late recurrences are possible.
For many stage 4 patients today, the realistic goal is living with cancer as a chronic, managed condition rather than eliminating it entirely. Treatments can shrink tumors, hold the disease stable, and maintain quality of life for extended periods.
Exceptional Responders
A small but real group of stage 4 patients have outcomes that defy expectations. The National Cancer Institute formally studies these cases through its Exceptional Responders Initiative. These are patients who achieve complete or lasting partial responses to treatments that work in fewer than 10% of patients, and who sustain that response at least three times longer than typical.
What makes someone an exceptional responder isn’t fully understood, but genetics play a role. In the case that launched the initiative, a patient with metastatic bladder cancer had specific gene mutations that made the tumor uniquely vulnerable to a targeted drug. The patient achieved a complete response lasting over two years on a treatment that failed for nearly everyone else with the same cancer type. Researchers are studying tumor DNA from exceptional responders to identify patterns that could help match future patients with the right therapies.
Factors That Influence Your Odds
Survival statistics are population averages, and individual outcomes depend on several factors. The specific biology of your tumor matters enormously. Two people with the same cancer type and stage can have very different genetic mutations driving their disease, which affects how well treatments work. Lung cancers with certain targetable mutations, for example, respond to precision therapies that can extend survival well beyond the 10.5% average.
Age at diagnosis, overall physical fitness, how well you can tolerate treatment, and how many organs are involved all shape prognosis. Where the cancer has spread also matters: metastases in certain locations (like the brain or liver) generally carry a worse outlook than spread limited to bone or lymph nodes, depending on the cancer type.
One large cohort study of nearly 6,000 cancer patients found that about 17.5% were already metastatic at the time of their initial diagnosis. In that study, researchers looked at whether physical activity before diagnosis affected the likelihood of being diagnosed at an advanced stage and found no significant connection. However, physical fitness does influence how well patients tolerate aggressive treatment regimens, which can indirectly affect outcomes.
How to Read Survival Statistics
Five-year survival rates reflect patients diagnosed years ago, not patients starting treatment today. Cancer treatment is evolving quickly enough that current outcomes for many cancers are better than what the statistics show. This lag is especially relevant for cancers where immunotherapy or targeted drugs became standard only recently.
These statistics also represent averages across all ages, health levels, and treatment approaches. A relatively young, otherwise healthy patient with a cancer type that responds to newer therapies may have a considerably better outlook than the published number suggests. Conversely, an older patient with multiple health problems may face steeper odds.
The most useful way to interpret these numbers is as a starting point for a conversation, not a verdict. Your oncologist can give you a more personalized picture based on the specific characteristics of your cancer, your treatment options, and how your body is responding.